Drug Profile

VY 2149

Alternative Names: VY-2149

Latest Information Update: 14 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

29 Apr 2025 Vivoryon Therapeutics has patent pending for medical use for varoglutamstat and backup compounds/VY2149, as well as on dosing regimens and on the use of varoglutamstat and related structures (e.g. VY2149) for the treatment of kidney diseases
29 Apr 2025 Vivoryon Therapeutics has patent pending for QPCT/L inhibitors (varoglutamstat and VY2149) in combination with SGLT2 inhibitors
04 Mar 2025 Vivoryon Therapeutics plans a phase IIb trial for Type 2 diabetes mellitus and diabetic nephropathies

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com